As with primaquine, tafenoquine can cause severe hemolytic anemia in people with G6PD deficiency. Those with partial deficiency that may be missed by qualitative testing may also be at risk for hemolysis. Chloroquine ireland Hydroxychloroquine 200 mg tablet Jun 16, 2016 In Indonesia, chloroquine has been replaced by artemisinin-based combination therapy i.e. ACTs due to widespread chloroquine resistance. This study will evaluate the efficacy and safety of a single dose of tafenoquine when co-administered with an ACT i.e. DHA-PQP. Tafenoquine is an 8-aminoquiniline related to primaquine with pre-clinical activity against a range of malaria species. We treated two acute cases of vivax malaria with tafenoquine 800 mg over three days alone, instead of conventional chloroquine 1500 mg over three days and primaquine 420 mg over 14 days. Provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex updated, Cerner Multum™ updated, Wolters Kluwer™ updated. Tafenoquine use in people with G6PD deficiency or unknown G6PD status is contraindicated. Therefore, physicians must perform G6PD testing before prescribing tafenoquine. Act with chloroquine tafenoquine Tafenoquine approved by US FDA for radical cure of vivax., Treatment of acute vivax malaria with tafenoquine. Lupus hydroxychloroquine side effectsHydroxychloroquine foods to avoidEffects of stop taking plaquenil Tafenoquine, an 8-aminoquinoline drug related to primaquine, is only the second drug of its class to receive FDA approval. Tafenoquine kills both the liver and blood stages of the parasite, broadening its applicability for chemoprophylaxis to all species of malaria. Guidance for Using Tafenoquine for Prevention and Antirelapse.. Tafenoquine Dosage Guide with Precautions -. CDC - Malaria - New antimalarial tafenoquine. Chloroquine binds to heme or FP to form the FP-chloroquine complex; this complex is highly toxic to the cell and disrupts membrane function. Action of the toxic FP-chloroquine and FP results in cell lysis and ultimately parasite cell autodigestion. Tafenoquine is an investigational medicine that has completed phase III studies. If approved, it would be the first new medicine for relapsing malaria in over 60 years. Tafenoquine will potentially offer a single-dose cure for the liver-stage of P. vivax infections and will be administered alongside a standard 3-day chloroquine or potentially an ACT treatment regimen. Single-dose tafenoquine 300 mg coadministered with chloroquine for P vivax malaria relapse prevention was more efficacious than chloroquine alone, with a similar safety profile. As a result, it has been selected for further clinical assessment in phase 3.